3251 related articles for article (PubMed ID: 7734956)
1. Tetramodality treatment of human melanoma in vitro.
Auzenne E; Feig B; Ross MI; Tomasovic SP; Klostergaard J
Melanoma Res; 1995 Feb; 5(1):49-57. PubMed ID: 7734956
[TBL] [Abstract][Full Text] [Related]
2. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.
Liénard D; Lejeune FJ; Ewalenko P
World J Surg; 1992; 16(2):234-40. PubMed ID: 1561804
[TBL] [Abstract][Full Text] [Related]
3. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
[TBL] [Abstract][Full Text] [Related]
4. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
[TBL] [Abstract][Full Text] [Related]
5. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma.
Clark J; Grabs AJ; Parsons PG; Smithers BM; Addison RS; Roberts MS
Melanoma Res; 1994 Dec; 4(6):365-70. PubMed ID: 7703715
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia.
Robins HI; d'Oleire F; Kutz M; Bird A; Schmitt-Tiggelaar CL; Cohen JD; Spriggs DR
Cancer Lett; 1995 Feb; 89(1):55-62. PubMed ID: 7882302
[TBL] [Abstract][Full Text] [Related]
7. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
8. [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase].
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S
Tumori; 2003; 89(4 Suppl):241-3. PubMed ID: 12903606
[TBL] [Abstract][Full Text] [Related]
9. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
Fraker DL; Alexander HR
Important Adv Oncol; 1994; ():179-92. PubMed ID: 8206489
[No Abstract] [Full Text] [Related]
10. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
[TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines.
Schiller JH; Bittner G
Int J Cancer; 1990 Jul; 46(1):61-6. PubMed ID: 2114374
[TBL] [Abstract][Full Text] [Related]
12. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors.
Schienk S; Liénard D; Gerain J; Baumgartner M; Lejeune FJ; Chiquet-Ehrismann R; Rüegg C
Int J Cancer; 1995 Nov; 63(5):665-72. PubMed ID: 7591283
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia.
Robins HI; Katschinski DM; Longo W; Grosen E; Wilding G; Gillis W; Kraemer C; Tiggelaar CL; Rushing D; Stewart JA; Spriggs D; Love R; Arzoomanian RZ; Feierabend C; Alberti D; Morgan K; Simon K; d'Oleire F
Cancer Chemother Pharmacol; 1999; 43(5):409-14. PubMed ID: 10100597
[TBL] [Abstract][Full Text] [Related]
14. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
15. Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease.
Robins HI; D'Oleire F; Grosen E; Spriggs D
Anticancer Res; 1997; 17(4B):2891-4. PubMed ID: 9329556
[TBL] [Abstract][Full Text] [Related]
16. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients.
Feelders RA; Vreugdenhil G; Eggermont AM; Kuiper-Kramer PA; van Eijk HG; Swaak AJ
Eur J Clin Invest; 1998 Jul; 28(7):520-7. PubMed ID: 9726030
[TBL] [Abstract][Full Text] [Related]
17. Effects of interferons and tumour necrosis factor-alpha on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line.
Suarez Pestana E; Björklund G; Larsson R; Nygren P; Nilsson K; Bergh J
Acta Oncol; 1996; 35(4):473-8. PubMed ID: 8695164
[TBL] [Abstract][Full Text] [Related]
18. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases.
Rossi CR; Foletto M; Mocellin S; Pilati P; Lise M
Ann Surg Oncol; 2004 Feb; 11(2):173-7. PubMed ID: 14761920
[TBL] [Abstract][Full Text] [Related]
20. TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial.
Rossi CR; Russano F; Mocellin S; Chiarion-Sileni V; Foletto M; Pilati P; Campana LG; Zanon A; Picchi GF; Lise M; Nitti D
Ann Surg Oncol; 2008 Apr; 15(4):1218-23. PubMed ID: 18247095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
